The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis
Open accessAbstract
Importance: Cardiovascular adverse events (CVAEs) after treatment with BRAF and MEK inhibitors in patients with melanoma remain incompletely characterized. Objective: To determine the association of BRAF and MEK inhibitor treatment with CVAEs in patients with melanoma compared with BRAF inhibitor monotherapy. Data Sources: PubMed, Cochrane, and Web of Science were systematically searched for keywords vemurafenib, dabrafenib, encorafenib, trametinib, binimetinib, and cobinimetinib from database inception through November 30, 2018. Study Selection: Randomized clinical trials reporting on CVAEs in patients with melanoma being treated with BRAF and MEK inhibitors compared with patients with melanoma being treated with BRAF inhibitor monotherapy were selected. Data Extraction and Synthesis: Data assessment followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. Pooled relative risks (RRs) and 95% CIs were determined using random-effects and fixed-effects analyses. Subgroup analyses were conducted to assess study-level characteristics associated with CVAEs. Main Outcomes and Measures: The selected end points were pulmonary embolism, a decrease in left ventricular ejection fraction, arterial hypertension, myocardial infarction, atrial fibrillation, and QTc interval prolongation. All-grade and high-grade (≥3) CVAEs were recorded. Results: Overall, 5 randomized clinical trials including 2317 patients with melanoma were selected. Treatment with BRAF and MEK inhibitors was associated with an increased risk of pulmonary embolism (RR, 4.36; 95% CI, 1.23-15.44; P = .02), a decrease in left ventricular ejection fraction (RR, 3.72; 95% CI, 1.74-7.94; P < .001), and arterial hypertension (RR, 1.49; 95% CI, 1.12-1.97; P = .005) compared with BRAF inhibitor monotherapy. The RRs for myocardial infarction, atrial fibrillation, and QTc prolongation were similar between the groups. These results were consistent when assessing high-grade CVAEs (left ventricular ejection fraction: RR, 2.79; 95% CI, 1.36-5.73; P = .005; I2 = 29%; high-grade arterial hypertension: RR, 1.54; 95% CI, 1.14-2.08; P = .005; I2 = 0%), but RRs for high-grade pulmonary embolism were similar between groups. A higher risk of a decrease in left ventricular ejection fraction was associated with patients with a mean age younger than 55 years (RR, 26.50; 95% CI, 3.58-196.10; P = .001), and the associated risk of pulmonary embolism was higher for patients with a mean follow-up time longer than 15 months (RR, 7.70; 95% CI, 1.40-42.12; P = .02). Conclusions and Relevance: Therapy with BRAF and MEK inhibitors was associated with a higher risk of CVAEs compared with BRAF inhibitor monotherapy. The findings may help to balance between beneficial melanoma treatment and cardiovascular morbidity and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70024-x · Cited by 640
Self-citationNitrite regulates hypoxic vasodilation via myoglobin-dependent nitric oxide generation
Totzeck, M., Hendgen-Cotta, U. B., Luedike, P., Berenbrink, M., Klare, J. P., Steinhoff, H.-J., Semmler, D., Shiva, S., Williams, D., Kipar, A., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.087155 · Cited by 202
Self-citation
Research works printed but not linked: 36
- Schadendorf, 2018, Melanoma., Lancet, 392, 971, 10.1016/S0140-6736(18)31559-9 · DOI · Paper page
- Bronte, 2015, What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment., Oncotarget, 6, 35589, 10.18632/oncotarget.v6i34 · doi:10.18632/oncotarget.v6i34
- Schadendorf, 2017, Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials., Eur J Cancer, 82, 45, 10.1016/j.ejca.2017.05.033 · DOI · Paper page
- Solit, 2011, Resistance to BRAF inhibition in melanomas., N Engl J Med, 364, 772, 10.1056/NEJMcibr1013704 · DOI · Paper page
- Robert, 2015, Improved overall survival in melanoma with combined dabrafenib and trametinib., N Engl J Med, 372, 30, 10.1056/NEJMoa1412690 · DOI · Paper page
- Dummer, 2018, Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial., Lancet Oncol, 19, 1315, 10.1016/S1470-2045(18)30497-2 · DOI · Paper page
- Long, 2017, Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma., N Engl J Med, 377, 1813, 10.1056/NEJMoa1708539 · DOI · Paper page
- Long, 2017, Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study., Ann Oncol, 28, 1631, 10.1093/annonc/mdx176 · DOI · Paper page
- Ascierto, 2016, Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial., Lancet Oncol, 17, 1248, 10.1016/S1470-2045(16)30122-X · DOI · Paper page
- Hauschild, Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma., J Clin Oncol
- Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial., Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X · DOI · Paper page
- Flaherty, 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma., N Engl J Med, 367, 107, 10.1056/NEJMoa1203421 · DOI · Paper page
- Larkin, 2014, Combined vemurafenib and cobimetinib in BRAF-mutated melanoma., N Engl J Med, 371, 1867, 10.1056/NEJMoa1408868 · DOI · Paper page
- Dummer, 2018, Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol, 19, 603, 10.1016/S1470-2045(18)30142-6 · DOI · Paper page
- Livingstone, 2014, BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management., Chin Clin Oncol, 3, 29
- Banks, 2017, Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism., Cardiovasc Toxicol, 17, 487, 10.1007/s12012-017-9425-z · doi:10.1007/s12012-017-9425-z
- Kubin, 2017, The MEK1 inhibitors UO126 and PD98059 block PDGF-AB induced phosphorylation of threonine 292 in porcine smooth muscle cells., Cytokine, 95, 51, 10.1016/j.cyto.2017.02.003 · DOI
- Liu, 2017, BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma., Oncotarget, 8, 69477, 10.18632/oncotarget.17704 · DOI
- Rose, 2010, Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale., Physiol Rev, 90, 1507, 10.1152/physrev.00054.2009 · DOI · Paper page
- Viera, 2008, Odds ratios and risk ratios: what’s the difference and why does it matter?, South Med J, 101, 730, 10.1097/SMJ.0b013e31817a7ee4 · DOI · Paper page
- Zhu, 2017, Increased apoptosis in the paraventricular nucleus mediated by AT1R/Ras/ERK1/2 signaling results in sympathetic hyperactivity and renovascular hypertension in rats after kidney injury., Front Physiol, 8, 41, 10.3389/fphys.2017.00041 · DOI
- Bronte, 2015, Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy., Expert Opin Drug Saf, 14, 253, 10.1517/14740338.2015.986092 · DOI
- Rassaf, 2003, NO adducts in mammalian red blood cells: too much or too little?, Nat Med, 9, 481, 10.1038/nm0503-481 · DOI
- Abdel-Rahman, 2016, Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data., Clin Transl Oncol, 18, 848, 10.1007/s12094-015-1438-0 · DOI
- Liu, 2017, Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials., Oncotarget, 8, 32258, 10.18632/oncotarget.15632 · DOI
- Ponikowski, 2016, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC., Eur Heart J, 37, 2129, 10.1093/eurheartj/ehw128 · DOI · Paper page
- Larkin, 2014, Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study., Lancet Oncol, 15, 436, 10.1016/S1470-2045(14)70051-8 · DOI · Paper page
- Ascierto, 2013, Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma., J Clin Oncol, 31, 3205, 10.1200/JCO.2013.49.8691 · DOI · Paper page
- Long, 2015, Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial., Lancet, 386, 444, 10.1016/S0140-6736(15)60898-4 · DOI · Paper page
- Chapman, 2017, Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study., Ann Oncol, 28, 2581, 10.1093/annonc/mdx339 · DOI · Paper page
- Maio, 2018, Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial., Lancet Oncol, 19, 510, 10.1016/S1470-2045(18)30106-2 · DOI · Paper page
- Zamorano, 2016, 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)., Eur Heart J, 37, 2768, 10.1093/eurheartj/ehw211 · DOI · Paper page
- Totzeck, 2019, Cardio-oncology: strategies for management of cancer-therapy related cardiovascular disease., Int J Cardiol, 280, 163, 10.1016/j.ijcard.2019.01.038 · DOI · Paper page
- Welsh, 2015, Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma., Ther Adv Med Oncol, 7, 122, 10.1177/1758834014566428 · DOI · Paper page
- Knispel, 2018, The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma., Expert Opin Drug Saf, 17, 73, 10.1080/14740338.2018.1390562 · DOI
- HigginsJPT, GreenD. Cochrane Handbook for Systematic Reviews of Interventions. http://handbook-5-1.cochrane.org/. Accessed June 27, 2019. · DOI · Paper page
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Self-citationLyon, A. R., Dent, S., Stanway, S., Earl, H., Brezden-Masley, C., Cohen-Solal, A., Tocchetti, C. G., Moslehi, J. J., Groarke, J. D., Bergler-Klein, J., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1920 · Cited by 815
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Self-citationValidity of data extraction in evidence synthesis practice of adverse events: reproducibility study
Xu, C., Yu, T., Furuya-Kanamori, L., Lin, L., Zorzela, L., Zhou, X., Dai, H., Loke, Y., & Vohra, S. (2022) · BMJ · doi:10.1136/bmj-2021-069155 · Cited by 82
Metadata
- Authors
- Mincu, R. I., Mahabadi, A. A., Michel, L., Mrotzek, S. M., Schadendorf, D., Rassaf, T., & Totzeck, M.
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2019-08-09
- Volume
- 2
- Issue
- 8
- Pages
- e198890
- ISSN
- 2574-3805 (ISSN-L)
- OpenAlex
- W2968344727
- Cited by
- 170
- References
- 6
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1001/jamanetworkopen.2019.8890
- The paper
- Mincu, R. I., Mahabadi, A. A., Michel, L., Mrotzek, S. M., Schadendorf, D., Rassaf, T., & Totzeck, M. (2019). Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2019.8890
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.